Clinical Trials Logo

Clinical Trial Summary

The purpose of the research protocol is to evaluate the effectiveness of Cinnamomum verum extract for the initiation of labor. Cinnamaldehyde ((E)-3-Phenylprop-2-enal) is an α, β unsaturated aromatic aldehyde, derived from cinnamon (Cinnamomum Verum oil) used as a flavoring; It is a clear yellowish liquid substance, with a strong odor and flavor. It is the main component of cinnamon (63%), giving it its physicochemical properties. Cinnamon has been an element of empirical use for the beginning of labor, however, its effectiveness has not been demonstrated. Cinnamon has been reported for its ethnopharmacological properties in pregnancy, being used to facilitate childbirth, as a lactagogue and for postpartum recovery. In Honduras, its use has been reported to relieve nausea and vomiting during pregnancy, to reduce abdominal pain. , reduction of lower limb edema, to relieve anxiety during labor, as well as a lactagogue without convergent opinions.


Clinical Trial Description

clinical trial of parallel groups of effectiveness, 2 groups will be taken, the intervention group will be administered capsules of Cinnamomum verum concentrate (1000 mg orally per day, a single dose) containing 67% cinnamaldehyde, one capsule per day will be administered (oral dose cinnamaldehyde lethal dose (LD50) of 1.15 g/kg), each capsule contains 1000 mg of Cinnamomum verum bark concentrate in soft gelatin capsules which are odorless and tasteless. The control group will be administered canola oil capsules, a dose of 400 mg orally per day, a single dose per day. These soft gelatin capsules are odorless and tasteless. Both capsules have identical physical characteristics. (they are soft gelatin capsules with the same color and smell) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06164613
Study type Interventional
Source Universidad Nacional Autonoma de Honduras
Contact Ricardo A. Gutierrez Ramirez, MD, MSc
Phone +50497546940
Email ricardo.gutierrez@unah.edu.hn
Status Recruiting
Phase Phase 2
Start date December 4, 2023
Completion date October 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT06343480 - Misoprostol Versus Oxytocin for Induction of Labour in Parturients With Spontaneous Rupture of Fetal Membranes at Term N/A
Not yet recruiting NCT03985618 - The MODE Trial: Planned Caesarean Section Versus Induction of Labour for Women With Class III Obesity N/A
Not yet recruiting NCT05510310 - Breast Stimulation vs. Low Dose Oxytocin Augmentation for Labor Induction Phase 1/Phase 2
Completed NCT06151925 - Laminaria Tents Versus Vaginal Prostaglandin in Cervical Ripening N/A
Completed NCT05084326 - Engagement of Fetal Head as a Predictor of a Successful Vaginal Delivery in Primigravidas Presented in Early Labor.
Completed NCT03670836 - Comparison of Misoprostol Ripening Efficacy With Dilapan Phase 4
Terminated NCT04564196 - Breath Metabolomics in the Laboring Parturient
Completed NCT04000438 - Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix Phase 2
Completed NCT05262738 - Misoprostol Dosing in BMI Greater Than 30 Phase 4
Withdrawn NCT05255263 - Goal-directed Labor Epidural Analgesia Maintenance N/A
Recruiting NCT05489315 - Quantifying the Impact of the Peanut Ball on the Duration of the Active Stage of Labor N/A
Not yet recruiting NCT05791630 - The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL) N/A
Completed NCT04933708 - LaPPS: Labor Podcast for Patient Satisfaction N/A
Not yet recruiting NCT03784092 - Effect Mobility During Induction of Labor on Time to Delivery. A Randomized Controlled Trial N/A
Completed NCT04271722 - Clinical Evaluation of Cervical Ripening in the Outpatient Setting N/A
Terminated NCT04504682 - Ambulation With Labor Epidural in Obese Women N/A